文献速递炎症性肠病

系统综述与Meta分析:益生菌在炎症性肠病中的疗效

Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2017-06-27

该系统综述与Meta分析检索至2016年11月,纳入22项随机对照试验,评估益生菌对溃疡性结肠炎(UC)和克罗恩病(CD)的疗效。结果显示VSL#3可能对活动性UC诱导缓解有效,益生菌预防静止期UC复发可能不劣于5-氨基水杨酸(5-ASA),但在CD中疗效仍不确定,需更多随机对照试验证据。

要点

  • VSL#3可能对活动性UC诱导缓解有效(RR=0.74,95%CI 0.63-0.87)。
  • 益生菌预防静止期UC复发与5-ASA相当(RR=1.02,95%CI 0.85-1.23)。
  • 益生菌在CD诱导缓解、预防复发及术后复发中均未见获益,疗效仍不确定。

核心结论

  • VSL#3可能对活动性UC诱导缓解有效。
  • 益生菌预防静止期UC复发可能不劣于5-ASA。
  • 益生菌在CD中的疗效仍不确定,需更多随机对照试验证据。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、EMBASE和Cochrane对照试验注册库至2016年11月。
  • 纳入22项随机对照试验,受试者为成人UC或CD患者,比较益生菌与5-ASA或安慰剂。
  • 合并二分类症状数据,计算活动性IBD未达缓解的相对风险(RR)或静止期IBD疾病活动复发的RR,附95%置信区间(CI)。

主要发现

  • 检索共识别12253条引文,22项随机对照试验符合纳入标准。
  • 益生菌对比安慰剂诱导活动性UC缓解无获益(未达缓解RR=0.86,95%CI 0.68-1.08)。
  • 仅考虑VSL#3试验时似有获益(未达缓解RR=0.74,95%CI 0.63-0.87)。
  • 益生菌预防UC复发与5-ASA相当(复发RR=1.02,95%CI 0.85-1.23)。
  • 益生菌在诱导活动性CD缓解、预防静止期CD复发或预防CD术后缓解期复发方面均无获益。

关键数值与推荐

  • 活动性UC益生菌对比安慰剂未达缓解RR=0.86(95%CI 0.68-1.08)。
  • 活动性UC仅VSL#3试验未达缓解RR=0.74(95%CI 0.63-0.87)。
  • 预防UC复发益生菌对比5-ASA的RR=1.02(95%CI 0.85-1.23)。

临床怎么用

  • VSL#3可能用于活动性UC诱导缓解。
  • 益生菌预防静止期UC复发可能不劣于5-ASA。
  • 益生菌在CD中的疗效仍不确定,需更多随机对照试验证据方可明确其用途。

局限性

  • 益生菌在CD中的疗效仍不确定,需更多随机对照试验证据方可明确其用途。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ulcerative colitis (UC) and Crohn's disease (CD) are inflammatory bowel diseases (IBD). Evidence implicates disturbances of the gastrointestinal microbiota in their pathogenesis. AIM: To perform a systematic review and meta-analysis to examine the efficacy of probiotics in IBD. METHODS: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (until November 2016). Eligible randomised controlled trials (RCTs) recruited adults with UC or CD, and compared probiotics with 5-aminosalicylates (5-ASAs) or placebo. Dichotomous symptom data were pooled to obtain a relative risk (RR) of failure to achieve remission in active IBD, or RR of relapse of disease activity in quiescent IBD, with 95% confidence intervals (CIs). RESULTS: The search identified 12 253 citations. Twenty-two RCTs were eligible. There was no benefit of probiotics over placebo in inducing remission in active UC (RR of failure to achieve remission=0.86; 95% CI=0.68-1.08). However, when only trials of VSL#3 were considered there appeared to be a benefit (RR=0.74; 95% CI=0.63-0.87). Probiotics appeared equivalent to 5-ASAs in preventing UC relapse (RR=1.02; 95% CI=0.85-1.23). There was no benefit of probiotics in inducing remission of active CD, in preventing relapse of quiescent CD, or in preventing relapse of CD after surgically induced remission. CONCLUSIONS: VSL#3 may be effective in inducing remission in active UC. Probiotics may be as effective as 5-ASAs in preventing relapse of quiescent UC. The efficacy of probiotics in CD remains uncertain, and more evidence from RCTs is required before their utility is known.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Derwa Y, Gracie DJ, Hamlin PJ, et al. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. 2017. PMID: 28653751. doi:10.1111/apt.14203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。